Selected recent publications of circulating tumor cell (CTC) detection


Circulating Tumor Cell Detection and Capture by Photoacoustic Flow Cytometry in Vivo and ex Vivo.
Galanzha EI, Zharov VP. Cancers (Basel). 2013 Dec 10;5(4):1691-738. doi: 10.3390/cancers5041691. PMID: 24335964 [PubMed] Free PMC Article

Circulating tumor cells: clinically relevant molecular access based on a novel CTC flow cell.
Winer-Jones JP, et al. PLoS One. 2014 Jan 29;9(1):e86717. doi: 10.1371/journal.pone.0086717. eCollection 2014. PMID: [PubMed - in process] Free PMC Article

Detection of live circulating tumor cells by a class of near-infrared heptamethine carbocyanine dyes in patients with localized and metastatic prostate cancer.
Shao C, et al. PLoS One. 2014 Feb 14;9(2):e88967. doi: 10.1371/journal.pone.0088967. eCollection 2014. PMID: 24551200 [PubMed - in process] Free PMC Article

Circulating tumor cells: liquid biopsy.
Alix-Panabières C, Pierga JY.Bull Cancer. 2014 Jan 1;101(1):17-23. doi: 10.1684/bdc.2014.1883. Review. French.

Expression of Stem Cell and Epithelial-Mesenchymal Transition Markers in Circulating Tumor Cells of Breast Cancer Patients.
Krawczyk N, et al. Biomed Res Int. 2014;2014:415721. Epub 2014 May 8. Review.PMID: 24895575 [PubMed - as supplied by publisher] Free PMC Article

A novel flow cytometry-based cell capture platform for the detection, capture and molecular characterization of rare tumor cells in blood.
Watanabe M, et al. J Transl Med. 2014 May 23;12(1):143. [Epub ahead of print] PMID: 24886394 [PubMed - as supplied by publisher] Free Article

Circulating tumor cell identification by functionalized silver-gold nanorods with multicolor, super-enhanced SERS and photothermal resonances.
Nima ZA, et al. Sci Rep. 2014 May 9;4:4752. doi: 10.1038/srep04752. PMID: 24810323 [PubMed - in process] Free PMC Article

Evaluation of two different analytical methods for circulating tumor cell detection in peripheral blood of patients with primary breast cancer.
Jaeger BA, et al. Biomed Res Int. 2014;2014:491459. doi: 10.1155/2014/491459. Epub 2014 Apr 8. PMID: 24800234 [PubMed - in process] Free PMC Article

A novel oxygen carrier "YQ23" suppresses the liver tumor metastasis by decreasing circulating endothelial progenitor cells and regulatory T cells.
Li CX, et a. BMC Cancer. 2014 Apr 27;14(1):293. doi: 10.1186/1471-2407-14-293. PMID: 24766798 [PubMed - in process] Free PMC Article

Development of a new rapid isolation device for circulating tumor cells (CTCs) using 3D palladium filter and its application for genetic analysis.
Yusa A, et al. PLoS One. 2014 Feb 11;9(2):e88821. doi: 10.1371/journal.pone.0088821. eCollection 2014. PMID:24523941[PubMed - in process] Free PMC Article

Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-small-cell lung cancer patients.
Breitenbuecher F, et al. PLoS One. 2014 Jan 21;9(1):e85350. doi: 10.1371/journal.pone.0085350. eCollection 2014. PMID: 24465542 [PubMed - in process] Free PMC Article

Cancer stem cell characteristics of circulating tumor cells. .
Tinhofer I, Saki M, Niehr F, Keilholz U, Budach V. Int J Radiat Biol. 2014 May 12:1-6. [Epub ahead of print]

Detection of live circulating tumor cells by a class of near-infrared heptamethine carbocyanine dyes in patients with localized and metastatic prostate cancer.
Shao C, et al. PLoS One. 2014 Feb 14;9(2):e88967. doi: 10.1371/journal.pone.0088967. eCollection 2014. PMID: 24551200 [PubMed - in process] Free PMC Article

Enhanced detection of metastatic prostate cancer cells in human plasma with lipid bodies staining.
Mitra R, Goodman OB, Le TT. BMC Cancer. 2014 Feb 15;14:91. doi: 10.1186/1471-2407-14-91. PMID: 24528787 [PubMed - in process] Free PMC Article

Precautious remarks on evaluating circulating tumor cells

  1. 50-70% of patients with clinically confirmed metastatic cancer harbor CTC in their periphery blood, whereas 30-50% have no detectable CTC.
  2. Over 30% of patients with no clinical sign of malignant or even benign tumors harbor CTC in their periphery blood.
  3. Over 30% of patients with stage I or II, or with no identifiable primary tumor develop metastatic diseases.
  4. About 50% of patients with positive lymph nodes do not progress to metastatic disease.